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Abstract
OBJECTIVES: We sought to study the indications, long-term occurrence, and predictors of permanent pacemaker implantation (PPI) after
isolated surgical aortic valve replacement with bioprostheses.
METHODS: The CAREAVR study included 704 patients (385 females, 54.7%) without a preoperative PPI (mean ± standard deviation age
75 ± 7 years) undergoing isolated surgical aortic valve replacement at 4 Finnish hospitals between 2002 and 2014. Data were extracted
from electronic patient records.
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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RESULTS: The follow-up was median 4.7 years (range 1 day to 12.3 years). Altogether 56 patients received PPI postoperatively, with the
median 507 days from the operation (range 6 days to 10.0 years). The PPI indications were atrioventricular block (31 patients, 55%) and
sick sinus syndrome (21 patients, 37.5%). For 4 patients, the PPI indication remained unknown. A competing risks regression analysis
(Fine–Gray method), adjusted with age, sex, diabetes, coronary artery disease, preoperative atrial fibrillation (AF), left ventricular ejection
fraction, New York Heart Association class, AF at discharge and urgency of operation, was used to assess risk factors for PPI. Only AF at dis-
charge (subdistribution hazard ratio 4.34, 95% confidence interval 2.34–8.03) was a predictor for a PPI.
CONCLUSIONS: Though atrioventricular block is the major indication for PPI after surgical aortic valve replacement, >30% of PPIs are
implanted due to sick sinus syndrome during both short-term follow-up and long-term follow-up. Postoperative AF versus sinus rhythm
conveys >4-fold risk of PPI.
Clinical trial registration: clinicaltrials.gov Identifier: NCT02626871




AVR Aortic valve replacement
LVEF Left ventricular ejection fraction
NYHA New York Heart Association
PPI Permanent pacemaker implantation
SAVR Surgical aortic valve replacement
SSS Sick sinus syndrome
INTRODUCTION
Aortic valve disease is the most common valvular defect requir-
ing surgical or percutaneous treatment. Degenerative valve calci-
fication increases as the population gets older. Fibrosis and
calcification in stenotic aortic valves may extend into the annulus,
interventricular septum and atrioventricular (AV) node [1].
Consequently defects in the AV conduction are relatively com-
mon in patients with aortic valve disease. Among these patients,
a subsequent aortic valve replacement (AVR) may result in fur-
ther AV conduction block necessitating implantation of a perma-
nent pacemaker (PPI) [2–6].
With the advent of transcatheter AVR, increased risk for PPI
shortly after procedure is well documented [7]. However, little is
known about PPI occurrence and indications after isolated surgi-
cal AVR (SAVR) with bioprostheses due to a lack of long-term fol-
low-up data after operation [8, 9]. Such data might be useful for
assessing risks and benefits of treatment options as well as for pa-
tient counselling in patients undergoing SAVR or transcatheter
AVR. Identification of patients at increased risk of PPI after SAVR
is clinically meaningful to prevent arrhythmic complications such
as syncope, exercise intolerance, heart failure and sudden death.
We sought to assess the incidence, timing, indications and pre-
dictors for PPI after isolated SAVR with a biological prosthesis.
PATIENTS AND METHODS
This study was conducted under the auspices of a multicentre
retrospective registry, CAREAVR (ClinicalTrials.gov Identifier:
NCT02626871), which includes patients who underwent isolated
SAVR with a bioprosthesis at 4 University Hospitals in Finland
(Turku, Oulu and Kuopio University Hospitals between 2002 and
2014 and Helsinki 2006–2014). For all the index patients, the
indication for SAVR was aortic stenosis. The aim of CAREAVR is
to assess the incidences of preoperative and postoperative atrial
fibrillation (AF), strokes and systemic embolisms, PPIs, major
bleeds, postpericardiotomy syndromes and mortality in patients
undergoing isolated SAVR with a bioprosthesis.
Altogether 704 SAVR patients without preoperative PPI were
included in the study. Patients who underwent any other major
concomitant cardiac surgery procedure were excluded from this
study. To obtain reliable and accurate follow-up data, only
patients from the hospitals’ catchment areas were included in
this study. All the major adverse events including PPI, cerebrovas-
cular events, bleeding and myocardial infarctions were treated in
the same index hospitals, and therefore, the patient follow-up for
adverse events can be considered reliable. The patient records
were individually reviewed with a structured data-collection pro-
tocol for preoperative and perioperative data, discharge data and
long-term follow-up events, including PPI, AF, stroke, bleeding
and mortality. The information about preoperative rhythm was
extracted from 12-lead preoperative EKG. The causes of death
were retrieved from Statistics Finland. This governmental office
monitors the time and causes of all deaths in Finland.
Data were entered in an electronic case-report form. An inde-
pendent third-party data monitor checked the integrity of the
data for each study site.
The study protocol was approved by the Medical Ethics
Committee of the Hospital District of Southwest Finland and the
ethics committee of the National Institute for Health and
Welfare. Because of the retrospective, registry-based nature of
the study, informed consent was not required. The study con-
forms to the Declaration of Helsinki.
Statistical analysis
The statistical analyses were performed using SPSS, version 24
(IBM Corporation, Armonk, NY, USA), and STATA, version 15
(StataCorp LLC, College Station, TX, USA). Continuous variables
were reported as mean ± standard deviation if normally distrib-
uted and as median (25th–75th percentiles) if they were skewed.
The data were tested for normal distribution using Kolmogorov–
Smirnov and Shapiro–Wilk tests. Categorical variables were de-
scribed as counts and percentages. Pearson v2, Fisher’s exact test,
unpaired t-test and Mann–Whitney test were used for univariable
analysis. Analyses were exploratory in nature. Competing risks re-
gression analysis (Fine–Gray method) implemented with STATA,
with all-cause mortality as a competing risk, adjusted with age,
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(preoperative EKG), left ventricular ejection fraction (LVEF), pre-
operative New York Heart Association (NYHA) class, rhythm at
discharge (AF versus sinus rhythm) and urgency of the operation
(elective, urgent and salvation), was used to assess risk factors for
PPI. The putative predictors were chosen on the basis of plausible
a priori biological link. Two-sided P-value <0.05 were considered
statistically significant.
RESULTS
The mean age of the patients was 75 ± 7 years and 385/704
(54.7%) were females. The follow-up was median 4.7 years (range
1 day to 12.3 years). Baseline characteristics of patients with and
without a forthcoming PPI are presented in Table 1. Patients with
a PPI had a higher preoperative NYHA class than those without
the need for a PPI and a larger proportion of them had verapamil
as a preoperative antiarrhythmic medication (Table 1). These
were the sole baseline differences observed between the groups.
Data pertaining to perioperative and postoperative characteris-
tics of interest are presented in Table 2, and data pertaining to
aortic valve disease and conduction abnormalities are presented
in Table 3.
A total of 179 patients (25.4%) had preoperative AF, almost
half of these being permanent AF (Table 1). The groups with and
without postoperative PPI had a similar prevalence of preopera-
tive AF. Altogether 479 (68.0%) patients had postoperative AF.
Fifty-six patients (8.0%) received PPI postoperatively, with the
median 507 days from the operation (range 6 days to 10.0 years).
Both groups (PPI versus no PPI) had similar late mortality rates
(19.6% vs 19.1%). The recorded reasons for death within these
groups included cancer-related death [1 vs 13 cases (1.8% vs
2.0%)], fatal bleed [0 vs 4 cases (0% vs 0.6%)], ischaemic heart dis-
ease (ICD–10 (International Classification of Diseases) I20.0–25.9)
[1 vs 17 cases (1.8% vs 2.6%)], stroke (ICD–10 I60.0–69.8) [0 vs 11
cases (0% vs 1.7%)] and other unspecified causes [4 vs 27 cases
(7.1% vs 4.2%)].
A Kaplan–Meier curve of PPI-free survival and the number of
index persons at risk are shown in Fig. 1. The PPI indications were
AV block (AVB) (31 patients, 55%) and sick sinus syndrome (SSS)
(21 patients, 37.5%). The PPI indication was unknown in 4 cases.
In a competing risks regression analysis (Fine–Gray method)
adjusted with age, sex, diabetes, coronary artery disease, preop-
erative AF (preoperative EKG), LVEF, NYHA class, AF at discharge
and urgency of operation, only AF at discharge (subdistribution
hazard ratio 4.34, 95% confidence interval 2.34–8.03) was a
Table 1: Preoperative data of 704 patients undergoing isolated aortic valve replacement divided into groups based on PPI
PPI (n = 56) No PPI (n = 648) P-value
Preoperative data
Age (years), mean ± SD 76 ± 7 75 ± 7 0.430
Females, n (%) 34 (60.7) 351 (54.2) 0.387
Weight (kg), mean ± SD 78 ± 23 78 ± 20 0.961
Height (cm), mean ± SD 164 ± 11 163 ± 20 0.947
BMI (kg/m2), mean ± SD 27.6 ± 5.4 28.1 ± 10.6 0.704
NYHA class, n (%) 0.099a
I 6 (10.7) 98 (15.1)
II 17 (30.4) 232 (35.)
III 26 (46.4) 272 (42.0)
IV 7 (12.5) 46 (7.1)
Heart rate, mean ± SD 68 ± 10 70 ± 14 0.269
EKG preoperatively, n (%) 0.293a
Sinus rhythm 44 (78.6) 491 (75.8)
Atrial fibrillation 5 (8.9) 87 (13.4)
Treatment for dyslipidaemia, n (%) 38 (67.9) 373 (57.6) 0.178
Treatment for diabetes, n (%) 13 (23.2) 138 (21.3) 0.484
Treatment for hypertension, n (%) 43 (76.8) 483 (74.5) 0.512
Coronary artery disease, n (%) 16 (28.6) 193 (29.8) 0.956
Previous myocardial infarction, n (%) 4 (7.1) 51 (7.9) 0.722
Previous percutaneous coronary intervention, n (%) 5 (8.9) 62 (8.0) 0.947
Previous coronary bypass, n (%) 4 (7.1) 24 (3.7) 0.254
Previous aortic valve surgery, n (%) 1 (1.8) 15 (2.3) 0.742
Active endocarditis, n (%) 3 (5.4) 17 (2.6) 0.294
Previous endocarditis, n (%) 2 (3.6) 5 (0.8) 0.057
Recent myocardial infarction, n (%) 0 13 (2.0) 0.265
Chronic lung disease, n (%) 10 (17.9 ) 120 (18.5 ) 0.965
Occlusive arterial disease (ASO), n (%) 5 (8.9) 35 (5.4) 0.342
Active smoking, n (%) 5 (8.9) 44 (6.8) 0.676
Preoperative anti-arrhythmic medication, n (%)
b-blocking agents 36 (64.3) 409 (63.6) 0.919
Verapamil 1 (1.8) 1 (0.2) 0.028
Amiodarone 2 (3.6) 8 (1.2) 0.160
Sotalol 0 1 (0.2) 0.768
Digoxin 3 (5.4) 45 (7.0) 0.643
Statistical tests: Pearson v2 test.
aGamma test.
ASO: arteriosclerosis obliterans; BMI: body mass index; NYHA: New York Heart Association functional classification; PPI: permanent pacemaker implantation; SD:
standard deviation.
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predictor for a PPI. The analysis summary is shown in Table 4. A to-
tal of 19 (34% of all PPIs) patients had the PPI within 30 days of the
AVR; of them, 11 (58%) had AVB and 6 (32%) had SSS, and for 2
patients, the indication was unknown. Cumulative incidence func-
tion for PPI (AF versus sinus rhythm at discharge) is shown in Fig. 2.
DISCUSSION
The main findings of the present study are: (i) one-third of PPIs
were due to SSS; (ii) timing of PPI is relatively uniform over the
first operative month; and (iii) AF at discharge was the only sig-
nificant predictor of PPI.
To the best of our knowledge, the significance of AF rhythm at
discharge has not been similarly associated with the indication of
PPI in prior SAVR studies.
Previous studies on PPI after isolated SAVR show that pre-
existing conduction system abnormalities are associated with an
increased risk of PPI [10, 11]. However, a more robust predictive
factor is an advanced aortic valve disease with severe calcification
and the consequent damage to the conduction system [12]. This
may be a marker of more diffuse atrial involvement in patients
Table 2: Perioperative and postoperative data of 704 patients undergoing isolated aortic valve replacement divided into groups
based on PPI
PPI (n = 56) No PPI (n = 648) P-value
Operative data
Operation status, n (%) 0.635a
Elective 53 (94.6) 603 (93.1)
Urgent 3 (5.4) 40 (6.2)
Salvage 0 1 (0.2)
Reoperation within 7 days, n (%) 3 (5.4) 21 (3.2) 0.530
In-hospital data
Elevated CK-MB (>100), n (%) 2 (3.6) 22 (3.4) 0.973
Length of hospital stay (days), mean ± SD 12 ± 7 11 ± 8 0.347
Postoperative data, n (%)
Cardioversion within 30 days 8 (14.3) 89 (13.7) 0.917
In-hospital AF paroxysm 32 (58.2) 297 (45.8) 0.078
AF at discharge 27 (48.2) 163 (25.2) <0.001
AF after discharge 16 (28.6) 243 (37.5) 0.184
Mortality (late) 11 (19.6) 124 (19.1) 0.926
30 Days 0 25 (3.9) 0.134
1 Year 2 (3.6) 43 (6.6) 0.368
5 Years 6 (10.7) 93 (14.4) 0.453
Statistical tests: Pearson v2 test.
aGamma test.
AF: atrial fibrillation; CK-MB: creatine kinase-MB; PPI: permanent pacemaker implantation; SD: standard deviation.
Table 3: Characteristics pertaining to aortic valve disease and conduction abnormalities in 704 patients undergoing isolated aortic
valve replacement divided into groups based on PPI
Characteristics PPI (n = 56) No PPI (n = 648) P-value
Preoperative AF, n (%) 16 (28.6) 163 (25.2) 0.877a
Permanent 6 (10.7) 79 (12.2) 0.835
Paroxysmal 10 (17.9) 83 (12.8) 0.424
Aortic valve max pressure gradient (n = 639), mean ± SD 74 ± 25 79 ± 22 0.087
Aortic valve mean gradient (n = 542), mean ± SD 43 ± 13 48 ± 14 0.012
Aortic regurgitation (n= 673), n (%) 29 (51.8) 353 (54.5) 0.402a
Aortic regurgitation degree, n (%)
1 49 (81.7) 517 (79.8)
2 9 (16.1) 75 (11.6)
3 1 (1.8) 38 (5.9)
4 1 (1.8) 14 (2.2)
Mitral valve regurgitation (n = 681), n (%) 39 (69.6) 343 (53.4) 0.074a
Mitral valve regurgitation degree, n (%)
2 10 (17.9) 75 (11.6)
3 1 (1.8) 15 (2.3)
Prosthetic AV diameter (mm), mean ± SD 23.1 ± 1.87 22.9 ± 2.31 0.496
Statistical tests: Pearson v2 test.
aGamma test.





























 user on 29 January 2021
undergoing SAVR. Indeed, only recently atrial cardiomyopathy
has been defined as a factor that may be present with aortic ste-
nosis [13].
Histological changes in the conduction system often develop
in patients with aortic valve disease. Yeo et al. [14] observed that
fibrosis and sclerosis of the conduction system account for about
half of the cases with AVB, but involvement of the mitral ring or
central fibrous body (i.e. right fibrous trigone) may be the most
common cause of complete heart block with a narrow QRS com-
plex in the elderly. Putative causes in the literature have ranged
from purely mechanical (e.g. elevated left ventricular pressure)
and ischaemic factors to more general, age-related processes,
such as exaggerated degenerative changes and primary degener-
ative disease of the conduction system [15, 16]. A possible molec-
ular mechanism might involve a homeodomain-only protein,
which is highly expressed in the adult murine cardiac conduction
system [17]. Aortic valve disease and aortic regurgitation, in par-
ticular, exacerbate the pathological process, resulting in fibrous
thickening of the endocardium of the ventricular septum. This
thickening process is likely to cause an impingement on the un-
derlying conducting tissue, which in the long run may contribute
to the deceleration and eventually block the AV conduction in
patients with aortic stenosis. However, the most important fac-
tors leading to AVB among SAVR patients relate to the irritation
of tissues and mechanical injury caused by the surgery (among
others, surgical sutures).
We hypothesize that the late appearance of AVB in our data is
due to the combined effects of mechanical irritation of tissues
during surgery as well as the consequent tissue damage that sub-
sists, despite careful decalcification and cautious suturing. Age-
related processes gradually cause further degenerative changes in
the tissues, ultimately crossing the threshold of sufficient damage
for AVB to develop.
However, the observational and retrospective nature of the
study is a limitation that prevents us to draw any definite conclu-
sions about the causes of AVB.
Prevalence of PPI after bioprosthetic SAVR was higher in the
present data than in previous studies [11, 12, 18–21]. Van
Mieghem et al. [11] reported a rate of PPI of 2.0% in a series of
734 patients within 30 days after SAVR, while 4.0% required PPI
>30 days after SAVR. Robich et al. [21] reported an incidence of
4.8% of PPI after SAVR alone in their data of 659 692 patients
from the Nationwide Inpatient Sample database. A pooled analy-
sis reported on PPI in 3.3% of patients after isolated aortic valve
replacement and of 5.9% after aortic valve replacement with or
without coronary artery bypass grafting [22]. Moreover, in older
studies conducted in the 1970s and 1980s, the prevalence of
AVR-related PPI ranged 1–6%, but the median age of patients in
these studies was lower compared to our study [18, 23].
Quite surprisingly, the first postoperative month is a period of
relatively uniform incidence of PPI, while the transcatheter AVR
experience emphasizes the first operative week. This difference
may be due to larger trauma caused by the open surgery.
Evidently, very few PPIs are made within the very first days as re-
cuperation of the conduction is still possible.
This study has important clinical implications. The patient pop-
ulation in question is highly prone to bradyarrhythmias not only
due to the disturbance of the conduction system but also due to
SSS. The latter is clearly more frequent than reported in the gen-
eral population [24, 25]. This is likely related to the causative
mechanisms of aortic valve disease including the fibrous thicken-
ing of the endocardium. It has been suggested that cannulation
of the right atrium for cardiopulmonary bypass could be a possi-
ble cause of a relatively late occurrence of SSS [26, 27]. In our
study, no detailed information about this or other operative inci-
dents could be obtained. However, according to our data, during
the first 30 postoperative days, the cumulative hazard rates of
PPI after SAVR for AVB and SSS, respectively, possibly reflect the
relatively slow development of SSS due to the mechanism pro-
posed above.
The relatively high incidence for the need of PPI and the signif-
icantly increased risk of PPI in conjunction with AF suggest that
some patients who have undergone bioprosthetic AVR and are
diagnosed with AF at discharge may need more careful monitor-
ing to alleviate symptoms as well as to minimize morbidity asso-
ciated with conduction anomalies.
Limitations
Methodologically, this study has several strengths. A validated,
structured case-report form was used at all study sites. As a
Figure 1: PPI-free survival displayed as a function of years from the index oper-
ation. Numbers at risk are indicated for each 2-year interval. CI: confidence in-
terval; PPI: permanent pacemaker implantation.
Figure 2: The CIF for PPI with SR/AF at discharge as covariates. AF: atrial fibrilla-
tion; CIF: cumulative incidence function; PPI: permanent pacemaker implanta-
tion; SR: sinus rhythm.
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quality control, a professional third party monitored the data and
found only minor issues. The main limitation of this study is the
retrospective nature of data. However, the data contain relatively
detailed information about the baseline characteristics, operative
procedures and parameters as well as the chosen outcome varia-
bles. The indications of PPI for each individual patient, the im-
plantation procedure and the consequent monitoring for clinical
outcomes were in general well reported at each hospital. The im-
pact of preoperative conduction disorders in EKG on PPI proba-
bility could not be reliably estimated with the data.
CONCLUSIONS
In conclusion, the incidence of PPI after bioprosthetic SAVR is
higher than previously documented. The difference was most evi-
dent in the early postoperative period, i.e. the first 30 days after
operation. Though AVB is the major indication for PPI after
SAVR, >30% of PPIs are implanted due to SSS during both short-
term follow-up and long-term follow-up. Postoperative AF versus
sinus rhythm at discharge was associated with higher incidence
of PPI, incurring >4-fold risk of the need for permanent pacing.
These findings highlight the need for better monitoring of
patients after hospital discharge and the significance of well-
delineated criteria to screen patients in a high risk for developing
cardiac arrhythmias after SAVR.
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Table 4: The competing risks regression model SHRs of postoperative pacemaker implantation with all-cause mortality as a compet-
ing risk
Variables Model 0 Model 1 Model 2
SHR 95% CI SHR 95% CI SHR 95% CI
Age (years) 1.03 0.99–1.08 1.02 0.98–1.07 1.01 0.96–1.06
Male gender 0.85 0.50–1.43 0.79 0.42–1.47 0.76 0.40–1.46
Treatment for diabetes 1.27 0.64–2.51 1.14 0.57–2.30
Coronary artery disease 0.94 0.46–1.91 0.97 0.46–2.04
Preoperative AF (preoperative EKG) 0.61 0.24–1.56 0.27a 0.10–0.72
NYHA (III–IV vs I–II) 1.26 0.69–2.31 1.37 0.74–2.50
LVEF (LVEF <40% vs >_40%) 1.26 0.37–4.31 1.14 0.31–4.25
Rhythm at discharge (AF versus SR) 4.34a 2.34–8.03
Operation status (urgent versus elective) 0.32 0.03–3.10
aStatistically significant.
AF: atrial fibrillation; CI: confidence interval; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association functional classification; PPI: permanent
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